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The corticotropin-releasing factor (CRF) system is the primary central mediator of stress-like states, coordinating behavioral, endocrine,
and autonomic responses to stress. Although induction of anorexia is a well documented effect of CRF receptor agonist administration,
the central sites and behavioral processes underlying this phenomenon are poorly understood. The present studies addressed this
question by examining the neuroanatomical, behavioral, and pharmacological mechanisms mediating decreases in feeding produced by
the CRF1 /CRF2 receptor agonist urocortin. Separate groups of food-restricted male Sprague Dawley rats were given infusions of urocortin
(0, 50, 125, 250 ng/0.5 l) into the lateral septum (LS) and immediately afterward were rated on a wide array of behaviors (locomotion,
rearing, grooming, stereotypies) including a microstructural analysis of ingestive behavior. Intra-LS urocortin infusion dose-
dependently reduced feeding and drinking while concomitantly increasing grooming, stereotypies, and ethological plus traditional
measures of anxiety-like responses in the elevated plus-maze. Urocortin infusion into neighboring sites (lateral ventricle, medial cau-
date) had no effects. Coinfusion into the LS of the mixed CRF1 /CRF2 receptor antagonist D-Phe-CRF(12– 41) (0, 100, 1000 ng/0.5 l) or the
novel selective CRF2 receptor antagonist Astressin2B (0, 500, 1000 ng/0.5 l) blocked urocortin-induced effects, but the CRF1-selective
antagonist NBI27914 (0, 500, 1000 ng/0.5 l) had no effect, although it completely reversed the behavioral sequelae of CRF when infused
into the basolateral amygdala. These results indicate that one of the modes through which the CRF system promotes anorexia is the
recruitment of stress-like states after stimulation of CRF2 receptors within the LS.
Key words: corticotropin-releasing factor; corticotropin-releasing hormone; CRH; ingestive behavior; anxiety; amygdala
Introduction
Corticotropin-releasing factor (CRF) receptor agonists potently
reduce food intake across species (Zorrilla et al., 2003). Yet,
whether these anorectic effects are dissociable from anxiety-
promoting actions remains unclear, because the CRF system is
the primary central mediator of stress responses and contributes
to the etiology of stress-related psychiatric illness (Dautzenberg
and Hauger, 2002; Reul and Holsboer, 2002; Bale and Vale,
2004). Given the current epidemic of obesity in the United States,
there is great interest in identifying agents that reduce ingestion
without producing such deleterious side effects; CRF2 receptor
agonists have been proposed as such (Zorrilla et al., 2003).
The CRF system exerts a complex regulatory influence over
feeding, the nature of which is dependent on receptor subtype,
peripheral versus central sites, exogenous versus endogenous
mechanisms, and gene knock-out strategies versus acute phar-
macological manipulations. Despite these numerous factors,
there is consensus that stimulation of CRF1 receptors reduces
feeding and recruits anxiety-like behaviors in multiple paradigms
regardless of the method of receptor targeting (genetic modifica-
tion or drug infusion) or the brain region studied (Zorrilla et al.,
2003). The function of the CRF2 receptor, however, is less
straightforward. A plethora of evidence suggests that CRF2 recep-
tor stimulation decreases feeding, but the role of CRF2 in stress-
like behaviors remains unclear. Some studies of CRF2 receptor
knock-out mice indicate that deletion of this receptor increases
anxiety-like responses, leading to the suggestion that stimulation
of CRF2 provides a tonic inhibitory influence over stress-like
states that may facilitate the “coping” responses after exposure to
stress (Bale et al., 2000; Coste et al., 2000; Kishimoto et al., 2000).
Yet, because basal expression of CRF was increased in CRF2
knock-out animals, an alternative explanation is that their en-
hanced stress-like responses were attributable to increased stim-
ulation of CRF1 receptors rather than CRF2 deletion itself. Recent
studies with intracerebroventricular delivery of the CRF2-
selective endogenous agonists urocortin2 and urocortin3 reveal
that these peptides cause a delayed-onset reduction in feeding
and gastric emptying, prompting the hypothesis that drugs tar-
geting this receptor may cause anorexia without anxiety-like ef-
fects (Zorrilla et al., 2003; Czimmer et al., 2006). Nevertheless,
several reports indicate that stimulation of CRF2 receptors re-
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cruits anxiety-like behaviors (Moreau et al., 1997; Ho et al., 2001;
Bakshi et al., 2002; Spina et al., 2002; Hammack et al., 2003;
Henry et al., 2006).
One factor contributing to the apparent discrepancy between
these theories of CRF2 receptor function is the paucity of studies
combining site-specific manipulations of CRF2-containing re-
gions (particularly extrahypothalamic sites) with a detailed ob-
servational analysis of the behaviors accompanying the alter-
ations in consumption (acute microstructural analysis of feeding
and concomitant rating of other behaviors to simultaneously as-
sess feeding and stress-like effects). The present studies addressed
these issues and also examined the relative contributions of CRF
receptor subtypes to these effects by characterizing the mecha-
nisms through which the CRF1/CRF2 agonist urocortin (UCN)
reduces feeding after microinfusion into the lateral septum (LS),
a site that has a high concentration of CRF2 receptors and UCN-
containing terminals and has been found recently to mediate




Ninety-three male Sprague Dawley rats (Charles River Laboratories, Wil-
mington, MA), weighing 290 –320 g at the beginning of each experiment,
were used in the present studies. Rats were pair housed in clear plastic
cages in a temperature- and humidity-controlled vivarium. During ex-
periments, animals were kept on a 20 h food-restriction schedule (food
removed at 5:00 P.M., food returned at 1:00 P.M., or on test days, at the
beginning of the test session). Lights in the animal colony were on a 12 h
light/dark cycle (lights on at 7:00 A.M.), and all testing occurred between
9:00 A.M. and 1:00 P.M. On arrival, rats were handled daily for 5 min by
the experimenters to minimize stress during experiments. Animal facil-
ities were approved by the Association for the Assessment and Accredi-
tation of Laboratory Animal Care; protocols were in accordance with the
Guiding Principles in the Care and Use of Animals provided by the
American Physiological Society and the guidelines of the National Insti-
tutes of Health. All efforts were made to prevent animal suffering and
minimize the number of animals used for the studies.
Surgery
All surgeries took place within 1 week of arrival. Rats were anesthetized
with sodium pentobarbital (50 mg/kg; Abbott Labs, North Chicago, IL)
and treated with 0.1 ml of atropine sulfate (Phoenix Pharmaceuticals, St.
Joseph, MO) to minimize respiratory distress. Using a stereotaxic appa-
ratus (David Kopf Instruments, Tujunga, CA), stainless steel cannulas
(23 gauge) were implanted bilaterally and affixed to the skull with dental
cement (Lang Dental, Wheeling, IL) and skull screws (Small Parts, Miami
Lakes, FL). Cannulas were aimed at the LS [anteroposterior (AP), 0.4
mm from bregma; mediolateral (ML), 0.8 mm from midline; dorso-
ventral (DV), 3.5 mm from skull surface], the lateral ventricle (LV)
(AP, 1.0 mm from bregma; ML, 1.4 mm from midline; DV, 2.1 mm
from skull surface), the medial caudate (MC) (AP, 0.4 mm from breg-
ma; ML, 2.2 mm from midline; DV, 2.5 mm from skull surface), or
the basolateral amygdala (BLA) (AP, 3.0 from bregma; ML, 5.0 mm
from midline; DV, 5.8 mm from skull surface) [all coordinates are
based on the atlas of Paxinos and Watson (1998)]. After surgery, rats
were allowed 5–7 d to recover, during which time daily health checks and
gentle handling were performed by the experimenter.
Drugs
UCN was obtained from Bachem-Peninsula Laboratories (Torrance,
CA) and was dissolved with 10 mM HCl and sterile distilled water to a
final pH of 6.5. The vehicle treatment for all experiments in which UCN
was administered was sterile distilled water, pH 6.5. NBI27914 (NBI), a
selective CRF1 receptor antagonist (Chen et al., 1996), was generously
donated by Dr. D. Grigoriadis (Neurocrine Biosciences, La Jolla, CA) and
was dissolved with sonication in a vehicle solution of 90% double-
distilled water, 5% ethanol, and 5% cremaphor EL (Sigma, St. Louis,
MO). This vehicle solution was used as the control treatment for all
experiments in which NBI was administered. Astressin2B, a selective and
long-acting CRF2 receptor antagonist (Rivier et al., 2002) (donated by
Dr. W. Vale, Salk Institute, La Jolla, CA), was dissolved in sterile distilled
water. Sterile distilled water was the vehicle treatment for all experiments
in which Astressin2B was administered. All doses (see below) were cal-
culated using the salt weight.
Microinfusion procedure
On all test days, animals were held gently, and their stylets were removed
and placed into 70% ethanol. Cannulas were cleaned with a dental
broach, and stainless steel injectors (30 gauge) were lowered so that they
extended below the tips of the cannulas, making the final DV coordinates
from skull surface 6.0 mm for the LS, 3.6 mm for the LV, 5.0 mm
for the MC, and 8.8 mm for the BLA. The injectors were attached to
polyethylene tubing, which was connected to 10 l Hamilton microsy-
ringes (Fisher Scientific, Pittsburgh, PA). The microsyringes were
mounted on a motorized pump (Harvard Apparatus, Holliston, MA). A
total of 0.5 l of vehicle or drug solution was delivered per side over 93 s
in each infusion. After the pump was shut off, the injectors were kept in
place for an additional 60 s to let the infusion bolus absorb into the tissue.
Injectors were then removed, stylets were replaced, and animals were
placed immediately into test cages for behavioral testing. Two to 3 d
before drug testing, all rats received a mock infusion in which injectors
were lowered but no solution was administered. The mock infusion was
intended to acclimate rats to the infusion procedure and to minimize
stress attributable to infusions on the test days. After the mock infusion,
animals were put into the test cages with food and water for 30 min to
acclimate to the test environment.
Behavioral testing
On test days, after drug administration, rats were placed with food (lab
chow) and water into test cages, which were identical to the rats’ home
cages but had a wire grate floor. Total duration, number of bouts (dis-
crete episode of each behavior lasting continuously for at least 5 s), and
mean duration of each bout were rated for 45 min for the following
behaviors: feeding, drinking, rearing, and grooming. In addition, the
latencies to feed and drink and the amount of food eaten (in grams) and
water drunk (in milliliters) were measured. Locomotion, defined as the
number of center-cage crosses, and stereotypies (perseverative oral be-
haviors directed toward inedible objects) were also measured. All of these
behaviors were scored simultaneously and continuously by a trained
experimenter (who was blind to the rats’ treatments) during the test
session; total food and water intake were calculated at the end of the
session by subtracting the posttest amounts from the pretest amounts
(correcting for the amount of food that spilled through the bottom of the
cage during the test session). For testing in the elevated plus-maze (ex-
periment 2 only), rats were placed individually into the center square of
the apparatus facing the same closed arm immediately after intra-LS
microinfusions. The apparatus was constructed from black Plexiglas,
consisted of closed arms (bordered on three sides by a 40-cm-high wall)
and open arms (no walls but bordered on three sides by a 0.5-cm-high
ledge) arranged in a “” configuration with like arms (each arm was 50
cm long  10 cm wide) opposite each other [based on the parameters
described previously (Heinrichs et al., 1992; Spina et al., 2000)], and was
located in the center of a quiet, dimly lit room. After placing the rat in the
plus-maze, the experimenter exited the room, and a video camera
mounted on the ceiling above the apparatus recorded the rats’ move-
ments for 5 min on videotape, which was subsequently scored (by an
experimenter blind to the rats’ treatment condition) for the following
measures: percentage of open arm time (seconds spent in open arms
divided by the total number of seconds in the closed arms plus the open
arms); percentage of open arm entries (number of entries into open arms
divided by the total number of entries into closed arms plus open arms);
number of stretch-attends (rat’s hindlegs in a closed arm while head and
forepaws stretch into the center or an open arm; proposed as an index of
threat-assessment behavior that is increased during stress-like states)
(Rodgers and Cole, 1993; Wall and Messier, 2001; Carobrez and Berto-
glio, 2005). It should be noted that avoidance of novel, bright, open
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environments (i.e., the open arms of the elevated plus-maze) is most
parsimoniously used as an operational definition of a stress-like state
(File, 1996). The experimenter was blind to treatment conditions
throughout all experiments.
Experimental design
Eight experiments were conducted in separate groups of experimentally
naive rats. In all studies except experiment 2, rats were placed on a food-
restriction schedule for the entire duration of the experiment (food re-
moved at 5:00 P.M., food returned at 1:00 P.M., or on test days, at the
beginning of the test session). Water was available ad libitum. In all
experiments in which repeated tested occurred, a minimum of 48 h
separated consecutive test days.
Intra-LS UCN infusion: detailed behavioral analysis. Experiment 1 ex-
amined the behavioral effects of UCN infusion into the LS. Rats were
given three different doses of UCN (50, 125, 250 ng/0.5 l/side) or vehi-
cle into the LS (n  8) and were immediately placed into test cages. The
doses of UCN used in the present experiment were chosen based on pilot
studies that characterized the behavioral effects of UCN agonist infusion
into various limbic structures (Bakshi et al., 2001). A repeated-measures
design was used, with dosage as a within-subjects factor. Therefore, all
rats received vehicle and all three doses of UCN over 4 counterbalanced
test days (with a minimum of 48 h between each test day). In separate
groups of experimentally naive rats (experiment 2), the effects of intra-LS
UCN infusion (0, 125 ng; n  6 –13 per treatment) on anxiety-like re-
sponses in the elevated plus maze were evaluated; each rat was acclimated
to the infusion procedure with mock infusions twice before the test day
but received infusions and was tested just once in the plus-maze imme-
diately after the intra-LS microinfusion (drug treatment as a between-
subjects factor).
Behavioral effects of UCN infusion into regions neighboring the LS. To
confirm that the behavioral effects observed after intra-LS infusion of
UCN were localized specifically to the LS and were not attributable to
diffusion of UCN to adjacent areas, the behavioral effects of UCN (0, 50,
125, 250 ng/0.5 l/side) infused into regions proximal to the LS were
determined. Thus, in experiment 3, rats (n  7) had cannulas aimed at
the LV, and in experiment 4, UCN infusions were made into the MC (n 
8). All aspects of the experimental design, infusion, and testing proce-
dures in experiments 3 and 4 were identical to those used in experiment 1.
CRF receptor mediation of LS effects: blockade of UCN-induced behav-
iors. To confirm the pharmacological specificity of UCN-induced effects
to the CRF system, experiment 5 examined the ability of the mixed CRF1/
CRF2 receptor antagonist D-Phe-CRF(12– 41) (D-Phe) to reverse the be-
havioral effects of intra-LS UCN in experimentally naive rats. Thus, in
two separate groups of rats, the effects of a low (100 ng; n  6) or high
(1000 ng; n  9) antagonist dose on UCN-induced effects were exam-
ined. In both studies, rats received intra-LS infusion of vehicle or D-Phe,
followed immediately by vehicle or UCN (250 ng), and then were tested
immediately afterward in the behavioral observation test cages. All rats
received all four treatment combinations (vehicle/vehicle, vehicle/UCN,
antagonist/vehicle, antagonist/UCN) in a counterbalanced order over 4
test days that were separated by at least 48 h. To determine the relative
contributions of the CRF1 and CRF2 subtypes to these effects, the abilities
of a CRF1-selective antagonist [NBI; CRF1/CRF2 affinity 10,000 (Chen
et al., 1996)] and a CRF2-selective antagonist [Astressin2B; CRF2/CRF1
affinity 500 –1000 (Rivier et al., 2002)] to block intra-LS UCN-induced
behavioral changes were assessed in experiments 6 and 7, using the same
design and protocol as the D-Phe experiment. Thus, in experiment 6, the
effects of either a moderate (500 ng; n  8) or a high (1000 ng; n  8) dose
of NBI were examined; in experiment 7, the effects of 500 ng (n  7) or
1000 ng (n  8) of Astressin2B were studied. Antagonist doses were
chosen based on our previous work indicating that this dose range pre-
vents the behavioral effects elicited by CRF agonist infusion into other
brain regions (Jochman et al., 2005).
CRF receptor mediation of BLA effects: positive control for CRF1 antag-
onism in LS. To verify that the doses of NBI that failed to alter UCN-
induced effects after intra-LS infusion were behaviorally active, an addi-
tional study was performed in experimentally naive rats (experiment 8;
n  8) in which NBI (0, 1000 ng) was infused into the BLA immediately
before infusion of CRF (0, 200 ng) into this site, using the within-subjects
counterbalanced design applied in experiments 5–7. Rats were then
tested in behavioral observation cages as described above. Our previous
work indicates that CRF infusions into the BLA cause dramatic reduc-
tions in feeding and increases in grooming behavior similar to those
observed in the present studies with UCN into LS (Jochman et al., 2005).
Based on this work, it was predicted that this dose of NBI would reverse
the intra-BLA CRF-induced anorexia.
Note that because UCN is the primary ligand that is expressed in the
LS, whereas CRF is the predominantly expressed ligand in the BLA
(Kozicz et al., 1998), we chose to infuse UCN in LS and CRF into amyg-
dala. Nevertheless, because UCN and CRF have very similar affinities for
the CRF1 receptor (Dautzenberg and Hauger, 2002) and we used similar
doses of UCN and CRF in our studies, it is reasonable to compare results
of the NBI experiments across these ligands. It also should be noted that
the dose of NBI that was used (1000 ng/side) is in excess of the concen-
tration required to bind all CRF1 receptors in the BLA (Bakshi et al., 2002;
D. Grigoriadis, personal communication). Given that the LS expresses far
fewer CRF1 receptors than the BLA (Dautzenberg and Hauger, 2002),
this dose of NBI would be more than enough to bind all CRF1 receptors
in the LS.
Histology
At the end of the experiments, rats were overdosed with sodium pento-
barbital (100 mg/kg) and perfused transcardially with isotonic saline
followed by 10% formalin. Brains were removed, stored in formalin,
frozen with powdered dry ice, and sliced into 60 m coronal sections
using a cryostat (Leica, Deerfield, IL). After staining with cresyl violet,
sections were examined under a microscope for the location of injector
tips. Animals whose injector tip placements fell outside the targeted brain
regions were excluded from analyses of behavioral data. For experiment
2 (intracerebroventricular UCN infusions), anesthetized rats received
intracerebroventricular infusion of 5 l of Chicago Sky Blue Dye
(Sigma). One minute after infusion of the dye, rats were decapitated and
brains were sliced into 1 mm sections and examined for the presence of
dye within ventricles distal to the infusion site. Only rats for which blue
dye was observed in the third and fourth ventricles were considered to
have accurate cannula placements in the LV. The experimenter was blind
to rats’ experimental grouping as well as the behavioral data at the time of
histological analyses.
Data analysis
For experiments 1– 4, in which UCN was infused into the LS, LV, or MC,
separate one-factor ANOVAs were used to analyze each behavioral mea-
sure, with drug dosage as the within-subjects factor and each behavioral
measure as different dependent variables. Subsequent Newman–Keuls
post hoc tests were performed to determine dosage effects in each site. For
experiments 5–7, in which rats were infused intra-LS with D-Phe, NBI, or
Astressin2B and then infused intra-LS with UCN, two-factor ANOVAs
were run for each behavioral measure, with antagonist pretreatment and
drug treatment as the within-subjects factors. Similarly, separate within-
subjects two-factor ANOVAs were used to analyze data from experiment
8 (intra-BLA CRF antagonists vs CRF). Post hoc comparisons were made
using Tukey’s test; the  level was set at 0.05.
Results
Experiments 1 and 2: UCN in LS reduces ingestive behaviors
and recruits stress-like responses
Figure 1 depicts the effects of intra-LS UCN infusion on ingestive
behaviors; all graphs, except J and I, depict data from the entire 45
min test session. ANOVA indicated a main effect of UCN admin-
istration on total food intake (F(3,18)  3.38; p  0.04), with the
highest dose of UCN significantly reducing grams of food in-
gested ( p  0.05) (Fig. 1A). No effects were observed on the
latency to begin eating or the total number of eating bouts, sug-
gesting that UCN infusion into LS did not alter the motivation to
begin feeding or the ability to initiate feeding bouts. UCN signif-
icantly reduced the total amount of time spent feeding (F(3,18) 
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3.15; p  0.05; main effect of UCN), which was most apparent
during the middle portion (16 –30 min after infusion) of the test
session (Fig. 1G) and reached statistical significance for the high-
est dose ( p  0.05). Moreover, examination of the average dura-
tion of a feeding bout revealed that UCN markedly reduced this
measure (F(3,18)  14.2; p  0.01) at all three doses ( p  0.05)
during the middle portion (minutes 16 –30 after infusion) of the
test session (Fig. 1 I). Thus, UCN infusion into LS caused a sig-
nificant reduction in food intake that was not accompanied by
alterations in feeding latency or number of feeding bouts but was
associated with reduced average feeding bout duration. This pro-
file of results suggests that intra-LS UCN did not affect motiva-
tion or ability to initiate feeding but significantly reduced the
ability to maintain feeding once it had been initiated.
A similar pattern of results was seen for drinking behavior.
Water intake was also decreased by intra-LS UCN infusion
(F(3,18)  5.89; p  0.01), with both the middle and highest dose
reaching statistical significance ( p  0.05) (Fig. 1B). No effects
were observed on latency to drink or total number of drinking
bouts, but a main effect of UCN treatment was indicated by
ANOVA for total time spent drinking (F(3,18)  7.37; p  0.01),
with all three doses producing this effect ( p  0.05 for 50 and 125
ng doses and p  0.01 for 250 ng dose). This effect was likely
caused by the significant decrease in the average duration of a
drinking bout produced by intra-LS UCN (F(3,18)  4.56; p 
0.02), which was statistically significant at the middle and highest
doses ( p  0.05), and mirrored the profile observed for feeding
(Fig. 1 J). Thus, as with feeding, intra-LS UCN decreased total
amount of water drunk, total time spent drinking, and average
drinking bout duration without affecting latency to drink or total
number of drinking bouts. As with feeding, this profile suggests
that UCN did not alter the motivation or ability to initiate drink-
ing but, rather, disrupted the maintenance of this behavior.
Figure 2 illustrates the effects of intra-LS UCN administration
on exploratory behaviors and stereotypies. These measures were
rated to evaluate the effects of intra-LS UCN on noningestive
behaviors and to determine the global behavioral profile of UCN
administration in the rats. No effects were seen on locomotion
(cage crossings), suggesting that the decrease in ingestive behav-
iors in these rats was not attributable to a change in general ac-
tivity levels. Rearing was slightly decreased by intra-LS UCN
(F(3,18)  8.08; p  0.01) at the highest dose ( p  0.05) (Fig. 2B).
Although the total number of grooming bouts were not affected,
the total time spent grooming (F(3,18)  4.79; p  0.02) was
significantly increased by the highest dose ( p  0.01) (Fig. 2D)
and was accompanied by a strong trend toward an increase in the
average duration of an individual grooming bout (F(3,18)  2.59;
p  0.08) (Fig. 2E). Interestingly, this grooming profile was com-
plementary to that seen for ingestive behaviors, with UCN alter-
ing the maintenance rather than the initiation of this displace-
ment behavior. In addition, infusion of UCN into the LS
markedly increased the incidence of oral and whole-body stereo-
typies: noningestive licking (licking of any objects including the
self that are not food or water), biting (of inedible objects), self-
gnawing, wet dog shakes, and freezing (F(3,18)  3.52; p  0.04),
particularly at the highest dose ( p  0.05) (Fig. 2F). Thus, the
same dose of UCN that decreased food intake after intra-LS ad-
ministration did not increase overall activity levels but did recruit
several displacement behaviors that are often associated with
stress (Berridge et al., 1999).
To more directly examine the relationship between stress-like
and ingestive behaviors induced by UCN infusion into the LS, the
effects of intra-LS infusion of a dose of UCN that failed to de-
crease food intake (125 ng) was assessed on behavior in the ele-
vated plus-maze. UCN infusion significantly decreased the per-
centage of time spent in the open arms (F(1,17)  8.29; p  0.02)
Figure 1. Microstructural analysis of eating (top row) and drinking (bottom row) after UCN infusion into LS. Shown are effects on total food/water intake over 45 min (A, B), latency to eat/drink
(C, D), total number of eating/drinking bouts in the entire test session (E, F ), total time spent eating/drinking during the entire session (G, H ), and average duration of an eating/drinking bout during
the middle portion (minutes 16 –30 after infusion) of the test session (I, J ). Values represent mean  SEM for each treatment. *p  0.05, compared with vehicle. VEH, Vehicle. UCN doses are in
nanograms per 0.5 l/side.
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and the percentage of open arm entries
(F(1,17)  6.19; p  0.03) (Fig. 3A,B), con-
sistent with the profile that is produced by
stress in this paradigm and which is pre-
sumed to indicate an anxiety-like state in
the rat (Koob et al., 1993). Moreover, a
pronounced increase in threat-assessment
behavior, as indexed by the number of
stretch-attends (Fig. 3C), was produced
by intra-LS UCN (F(1,17)  7.68; p 
0.02). These increases in stress-like behav-
iors in the elevated plus-maze were not
accompanied by general behavioral acti-
vation, because UCN infusion had no ef-
fect on the total number of arm entries
(Fig. 3D). Thus, a potent induction of
anxiety-like behaviors was recruited by
intra-LS infusion of a dose of UCN that
was half the concentration of that needed
to reduce food intake.
Experiments 3 and 4: no effects of UCN
infusion into regions neighboring
the LS
To determine the anatomical specificity of
the LS UCN effects, the behavioral se-
quelae of UCN infusion into regions
neighboring the LS were measured. Figure
4 illustrates the lack of any behavioral ef-
fects after UCN infusion into the LV or
MC, contrasting with the potent behav-
ioral effects following intra-LS UCN infu-
sions (as described above). Thus, the be-
havioral effects of intra-LS UCN infusion
could not be reproduced with infusion of
UCN into regions proximal to the LS, in-
dicating that these behavioral effects were
localized specifically to the LS and were not caused by diffusion of
UCN to the neighboring regions studied. For the sake of brevity,
only data for time spent feeding, time spent drinking, time spent
grooming, and stereotypy bouts are presented; however, no ef-
fects were observed on any behavior with UCN infusion into LV
or MC. The LS data are the same as those presented in Figures 1
and 2 but are presented again here adjacent to the LV and MC
results to illustrate the contrast between the sites.
Experiments 5–7: mixed CRF1 /CRF2 or CRF2-specific
antagonists, but not a selective CRF1 receptor antagonist,
block LS UCN effects
The effects of infusing the mixed CRF1/CRF2 antagonist D-Phe,
the CRF1-selective antagonist NBI, or the CRF2-selective antago-
nist Astressin2B into the LS on UCN-induced behaviors are de-
picted in Figure 5. For the sake of brevity, only the results from
the high-dose antagonist studies (1000 ng of each) are displayed;
however, the results of the low-dose antagonist experiments are
also described below. Food intake and grooming data are shown
to represent the two domains that intra-LS UCN altered (inges-
tive behavior and displacement behaviors).
Food intake
Coinfusion of the CRF1/CRF2 antagonist D-Phe into the LS
blocked intra-LS UCN-induced decreases in ingestive behavior,
as indicated by a significant main effect of UCN treatment (F(1,8)
 26.7; p  0.01) and a significant antagonist  agonist interac-
tion (F(1,8)  13.1; p  0.01) (Fig. 5A). Post hoc comparisons of
means revealed that UCN (250 ng) markedly reduced grams of
food eaten ( p  0.01), replicating the effect observed in the orig-
inal dose–response studies. In the D-Phe (1000 ng) plus UCN
condition, food intake values were significantly higher than those
for the vehicle plus UCN condition ( p  0.05) and were almost
back to control (vehicle/vehicle) levels although the antagonist
on its own did not affect food intake (F(1,8)  0.1; NS). Similarly,
pretreatment with the selective CRF2 receptor antagonist
Astressin2B also reversed UCN-induced anorexia. ANOVA indi-
cated a main effect of agonist treatment (F(1,7)  37.2; p  0.01)
and a significant antagonist  agonist interaction (F(1,7)  5.36;
p  0.05). Intra-LS UCN on its own was again found to reduce
food intake compared with the vehicle-alone condition ( p 
0.01), and pretreatment with Astressin2B significantly increased
gram intake values in UCN-treated rats ( p  0.05) so that they no
longer differed significantly from those of the vehicle/vehicle
condition. In contrast to the mixed or CRF2-selective antagonists,
the CRF1 antagonist NBI failed to alter UCN-induced decreases
in food intake. A main effect of agonist treatment was found with
ANOVA (F(1,7)  63.6; p  0.01), but no interaction between
antagonist and agonist treatment was seen (F(1,7)  0.6; NS). Post
hoc analyses indicated that both the UCN-alone ( p  0.01) and
the NBI/UCN ( p  0.01) conditions markedly reduced food
intake compared with the vehicle/vehicle condition; there was no
Figure 2. Effects of UCN infusion into LS on noningestive behaviors over a 45 min test session: A, locomotion; B, rearing; C, total
number of grooming bouts; D, total time spent grooming; E, average duration of a grooming bout; F, total number of stereotypy
bouts. Values represent mean  SEM for each treatment. p  0.08, *p  0.05, **p  0.01, compared with vehicle. VEH,
Vehicle. UCN doses are in nanograms per 0.5 l/side.
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difference between the UCN-alone and NBI/UCN conditions.
Thus, either a mixed CRF1/CRF2 or a selective CRF2 receptor
antagonist reverses the reduction in ingestive behavior elicited by
intra-LS UCN, but a selective CRF1 antagonist has no effect.
Grooming duration
Significant main effects of agonist treatment were observed in the
D-Phe (F(1,8)  24.6; p  0.01), the NBI (F(1,7)  67.7; p  0.01),
and the Astressin2B (F(1,7)  51.3; p  0.01) studies, with UCN
significantly increasing total grooming duration compared with
vehicle/vehicle values ( p  0.01) (Fig. 5B). A significant interac-
tion between antagonist and agonist treatments was seen in the
D-Phe study (F(1,8)  5.7; p  0.04), with post hoc comparisons of
means indicating that D-Phe/UCN grooming values were signif-
icantly lower than those for the vehicle/UCN condition ( p 
0.05) and that D-Phe/UCN values did not differ significantly from
those of the vehicle/vehicle condition. A similar profile was seen
with Astressin2B: there were trends toward a main effect of an-
tagonist treatment (F(1,7)  4.4; p  0.07) and an antagonist 
agonist interaction (F(1,7)  3.3; p  0.1), with coinfusion of the
CRF2 antagonist causing grooming duration values in UCN-
treated rats to be statistically indistinguishable from those of the
vehicle/vehicle condition. In contrast, NBI failed to alter UCN-
induced grooming (F(1,7)  0.2, p  0.69, main effect of antago-
nist; F(1,7)  0.2, p  0.68, antagonist  agonist interaction), with
NBI/UCN values that were nearly identical to those of the vehi-
cle/UCN condition and were significantly higher than those of
the vehicle/vehicle condition ( p  0.01). Thus, the mixed CRF1/
CRF2 antagonist and the selective CRF2 antagonist, but not the
CRF1 antagonist, blocked the behavioral effects of UCN infusion
into LS.
Low-dose antagonist experiments
In all three low-dose antagonist studies, significant main effects of
UCN treatment were seen for all the measures described above for
experiment 1, replicating the findings of this experiment. For the
sake of brevity, only the effects of feeding and grooming are de-
scribed. In all three studies, UCN significantly reduced feeding ( p 
0.01) while increasing displacement behaviors such as grooming
( p  0.01). Coinfusion of a low dose (100 ng) of D-Phe into the LS
had no effects on any UCN-induced behaviors. An interaction be-
tween pretreatment and treatment was seen after coinfusion of
Astressin2B at a lower dose (500 ng) for food intake (F(1,7)  6.4; p 
0.04), which during post hoc analyses revealed that food intake values
for the Astressin2B/UCN condition were significantly higher than
those for the UCN-alone condition ( p  0.05), although they still
differed significantly from those of the vehicle/vehicle treatment
( p  0.05). Thus, the lower dose of the CRF2-selective antagonist
caused a partial reversal of the UCN-induced anorectic effect. A
similar trend was observed for grooming duration, with 500 ng of
Astressin2B tending to partially reduce UCN-induced grooming,
although this effect did not reach statistical significance. In contrast,
the lower dose of the CRF1 antagonist NBI (500 ng) had no effects on
any UCN-induced behaviors.
Experiment 8: CRF1 receptor antagonist does block
behavioral effects of intra-BLA CRF administration
To verify that the doses of NBI used in the LS were sufficiently
high to produce behavioral effects, experiment 8 tested the hy-
pothesis that NBI would block the effects of CRF microinfusion
into the BLA, which we previously showed to cause decreases in
feeding and increases in grooming similar to those of UCN in the
LS (Jochman et al., 2005). Figure 6 displays the results of this
experiment. Only data for food intake and grooming duration are
shown, because these are representative of the two main domains
in which CRF agonists were found to affect behavioral responses.
For food intake, ANOVA revealed main effects of antagonist pre-
treatment (F(1,7)  7.5; p  0.03) and CRF treatment (F(1,7) 
13.6; p  0.01) and a significant interaction between antagonist
and agonist (F(1,7)  9.2; p  0.02). Post hoc comparisons of
means indicated that intra-BLA CRF infusion reduced food in-
take ( p  0.01), replicating our previously reported effect (Joch-
man et al., 2005), and that coinfusion of NBI completely blocked
this reduction ( p  0.01), with values in the NBI/CRF condition
indistinguishable from vehicle/vehicle levels (Fig. 6A). For time
spent grooming, ANOVA indicated main effects of pretreatment
(F(1,7)  8.3; p  0.03) and treatment (F(1,7)  7.9; p  0.03) and
a trend toward an interaction between those factors (F(1,7)  3.5;
p  0.1). Comparisons of means corroborated our previous find-
ing (Jochman et al., 2005) that intra-BLA CRF infusion dramat-
ically elevates grooming duration ( p  0.05) and that pretreat-
ment with NBI significantly reduces grooming in CRF-treated
rats ( p  0.05), with NBI/CRF values not differing from those of
the vehicle/vehicle condition. Thus, intra-BLA infusion of NBI,
at a dose that had no effects after intra-LS infusion, completely
blocked the behavioral effects of intra-BLA CRF.
Histological analyses
Figure 7 depicts the location of representative injector tip place-
ments for the LS, the MC, and the BLA. An experimenter blind to
Figure 3. Effects of intra-LS UCN infusion in the elevated plus-maze during a 5 min test
session: A, percentage of time spent in open arms; B, percentage of entries into open arms; C,
risk assessment indexed by the total number of stretch-attends; D, total entries into open and
closed arms. Values represent mean  SEM for each treatment. *p  0.05, compared with
vehicle. VEH, Vehicle. UCN doses are 125 ng/0.5 l/side.
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the rats’ treatments and behavioral data evaluated all placements
to determine whether or not injectors fell within the boundaries
of the targeted structures. Five LS placements (experiment 2),
two MC placements (experiment 4), and one LV placement were
found to be outside of the targeted regions, and the data from
these rats were thus excluded from all analyses; the sample sizes
given above reflect these histologically based omissions.
Discussion
The present results provide important insights into the neuro-
anatomical, behavioral, and pharmacological mechanisms un-
derlying the anorectic effects of UCN. First, the LS is a major
extrahypothalamic site underlying the anorectic effects of UCN,
because UCN infusion into LS but not neighboring regions re-
duces feeding behavior. Second, this anorectic effect does not
arise from deficits in the motivation or ability to initiate feeding,
but rather from a deficit in maintaining a prolonged feeding bout.
Recruitment of displacement behaviors may underlie this inabil-
ity to sustain ingestive responses, because doses of UCN that
reduce food intake potently elicit perseverative grooming and
oral stereotypies. Moreover, increased anxiety-like behaviors in
the elevated plus-maze are produced by doses lower than those
required to reduce food intake, additionally suggesting that re-
duced feeding after intra-LS UCN infusion may be secondary to
the elicitation of stress-like states. Finally, the behavioral effects of
intra-LS UCN are attributable to activation of CRF2 receptors,
because coinfusion of a mixed CRF1/CRF2 or a CRF2-selective
Figure 4. Behavioral sequelae of UCN infusion into sites adjacent to the LS during a 45 min test session. Shown are effects on total time spent eating (A), total time spent drinking (B), total time
spent grooming (C), and total number of stereotypy bouts (D). Values represent mean  SEM for each treatment. *p  0.05, **p  0.01, compared with vehicle. VEH, Vehicle. UCN doses are in
nanograms per 0.5 l/side.
Figure 5. Effects over a 45 min test session of intra-LS CRF receptor antagonists on UCN-
induced suppression of food intake (A) and increases in total time spent grooming (B). Values
represent mean  SEM for each treatment. **p  0.01, compared with VEH/VEH; p  0.05,
compared with VEH/UCN. VEH, Vehicle; ANTAG, antagonist. UCN doses are 250 ng/0.5 l/side.
Figure 6. Effects of intra-BLA CRF1 receptor antagonist infusion on CRF-induced suppression
of food intake (A) and increases in total time spent grooming (B) over a 45 min test session.
Values represent mean  SEM for each treatment. *p  0.05, **p  0.01, compared with
VEH/VEH; p  0.05, p  0.01, compared with VEH/CRF. VEH, Vehicle. Doses are as
follows: CRF, 200 ng/0.5 l/side; NBI, 1000 ng/0.5 l/side.
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antagonist but not a CRF1 antagonist completely blocks these
effects. Together, these findings suggest that stimulation of CRF2
receptors within the LS may promote anorexia through the in-
duction of stress-like responses.
These findings confirm an important role for the LS in UCN-
induced anorexia. It could be suggested that intra-LS UCN pro-
duces its behavioral effects via diffusion to the bed nucleus of the
stria terminalis (BNST), which also contains CRF2 receptors and
mediates anxiety-like behaviors (Erb and Stewart, 1999; Cooper
and Huhman, 2005) such that UCN-induced anorexia is medi-
ated by the LS but stress-like effects occur through the BNST. Yet,
given that stimulation of CRF receptors in BNST also induces
anorexia (Ciccocioppo et al., 2003), this possibility is not likely. It
also is unlikely that intra-LS UCN diffuses to BNST because the
primary route of diffusion would be up the injector tract but
BNST is ventral to LS. Our previous work indicates that the infu-
sion parameters used in the present studies allow for very ana-
tomically restricted effects within the LS, because infusion of CRF
system peptides into control sites such as the nucleus of the diag-
onal band (located ventral to the BNST and therefore more likely
than LS to permit diffusion into BNST) fails to produce effects
(Bakshi et al., 2002).
The present results are in agreement with those of Kotz and
colleagues, who found that deprivation- or hypocretin-induced
feeding are reduced by UCN infusion into LS (Wang and Kotz,
2002), and add to the growing body of literature indicating that
CRF receptor stimulation in either hypothalamic or extrahypo-
thalamic sites reduces food intake (Ohata
et al., 2000; Currie et al., 2001; Wang et al.,
2001; Daniels et al., 2004; Jochman et al.,
2005; Weitemier and Ryabinin, 2006).
The present studies also confirm our pre-
vious finding that CRF1 receptors within
the BLA regulate feeding (Jochman et al.,
2005). Importantly, the dose of CRF1 an-
tagonist that failed to affect intra-LS
UCN-induced effects is behaviorally ac-
tive in our feeding paradigms because this
dose administered into the BLA blocked
the effects of CRF, used in the same dose
range as UCN. Thus, multiple forebrain
and brainstem sites appear to mediate the
anorectic actions of CRF receptor
agonists.
Previous evidence indicates that stim-
ulation of either CRF1 or CRF2 receptors is
sufficient to reduce ingestive behavior
(Smagin et al., 1998; Cullen et al., 2001;
Zorrilla et al., 2003; Bale and Vale, 2004).
The present results provide the novel find-
ing that the contributions of these two re-
ceptors may be anatomically segregated,
with CRF1 receptors acting within the
amygdala and CRF2 receptors acting
within the LS in a parallel manner to reg-
ulate feeding. This notion of functionally
homogenous but anatomically heteroge-
neous actions of CRF receptor subtypes
also describes the nature of CRF1 and
CRF2 receptor regulation of stress-
induced defensive behaviors (Bakshi et al.,
2002). The Edinger-Westphal nucleus
(EW), which is the primary source of
UCN to the LS, regulates ingestive behavior, and UCN infusion
into other efferents of this nucleus also reduces feeding (Bitten-
court et al., 1999; Weitemier and Ryabinin, 2005, 2006). Given
that reduced feeding is accompanied by stress-like behaviors after
intra-LS UCN and that stressors potently activate UCN-
containing neurons of the EW, it is possible that the EW–LS
projection represents an important anatomical substrate mediat-
ing stress-induced anorexia (Gaszner et al., 2004). One might also
speculate that the periaqueductal gray (PAG), which receives
projections from the LS and amygdala, has a well validated role in
stress-induced behaviors, and has been implicated in the anorec-
tic actions of certain peptides (Marchand and Hagino, 1983;
Jenck et al., 1986; Kyrkouli et al., 1987; Kask et al., 2002), may
participate in intra-LS UCN-induced anorexia. It would be of
interest in future studies to determine whether the behavioral
sequelae of intra-LS UCN infusion or EW stimulation are antag-
onized by blockade of PAG activity.
To our knowledge, the present studies provide the first de-
tailed characterization of acute feeding microstructure with si-
multaneous evaluation of stress-related behaviors after site-
specific microinfusion of UCN and offer important new
information regarding the precise behavioral mechanisms
through which CRF receptor stimulation reduces feeding.
Intra-LS UCN significantly reduced food intake in the absence of
changes in the latency to begin feeding or the total number of
feeding bouts, suggesting that alterations in the motivation or
ability to begin feeding did not account for the anorectic effect of
Figure 7. Location of injector tip placements within the LS (A, B), the MC (C), and the BLA (D).
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UCN within the LS. Instead, the average duration of individual
feeding bouts was significantly reduced. A similar profile was
observed for drinking, indicating that UCN-induced effects were
not specific to feeding and that CRF2 receptor stimulation within
LS disrupted the maintenance rather than the initiation of inges-
tive behaviors. Although it remains to be determined whether
CRF2 receptor stimulation in LS triggers satiety mechanisms, as
has been suggested for intracerebroventricular infusion of uro-
cortin2 (Inoue et al., 2003), the present findings suggest that this
may not be the case after intra-LS UCN.
An alternative explanation is that feeding and drinking bouts
were terminated prematurely because of the recruitment of non-
ingestive behaviors that may reflect a stress-like interoceptive
state. Microstructural analysis of grooming revealed that the
same doses of UCN that reduced feeding bout duration markedly
increased the average duration of a grooming bout. Although
grooming can indicate satiety (Smith and Gibbs, 1992), it should
be noted that the pattern of grooming elicited by intra-LS UCN
did not fit the profile of the typical satiety sequence, because it was
not accompanied by other crucial markers of satiety such as a
reduction in meals or increased latency to initiate feeding. In-
stead, unusually long perseveration during each individual
grooming episode and a concomitant elicitation of oral stereo-
typies were observed, suggesting that CRF2 receptor stimulation
within LS promotes prolonged expression of displacement be-
haviors that may interfere with the maintenance of ingestive re-
sponses. The notion that perseverative grooming and oral stereo-
typies are indicators of stress-like states has been proposed
previously (Berridge et al., 1999); however, to the best of our
knowledge, the present results provide the first evidence for
the proposition that such a mechanism underlies the anorectic
effects of CRF2 receptor stimulation with LS. This proposed
mechanism of CRF2-mediated anorexia is in agreement with a
previous report demonstrating that decreases in feeding after
intracerebroventricular CRF infusion were significantly cor-
related with stress-like behaviors such as freezing and were
reversed by selective antagonism of CRF2 receptors (Pelley-
mounter et al., 2000).
Additional evidence for the hypothesis that the anorectic ac-
tions of UCN in LS are secondary to the recruitment of stress-like
states is provided by the finding that a lower dose of UCN than
that required to reduce food intake was sufficient to reduce open-
arm exploration in the elevated plus-maze. This hypothesis is in
contradiction to previous conceptualizations of the role of the
CRF2 receptor in ingestive behavior, which have argued that
stimulation of this receptor reduces feeding without inducing
anxiety-like effects (Zorrilla et al., 2003, 2004), a notion that is
based primarily on the finding that intracerebroventricular ad-
ministration of urocortin2 and urocortin3 can cause delayed re-
ductions in stress-like responses (Spina et al., 1996; Valdez et al.,
2002, 2003, 2004; Venihaki et al., 2004). Yet, multiple studies, in
addition to the present findings, indicate that particularly when
administered site-specifically into extrahypothalamic regions in-
cluding the LS, UCN or urocortin2 promotes stress-like behav-
iors through the activation of CRF2 receptors (Moreau et al.,
1997; Radulovic et al., 1999; Pelleymounter et al., 2000, 2002,
2004; Spina et al., 2002; Risbrough et al., 2003; Henry et al., 2006).
CRF2 receptor stimulation within some sites (i.e., hypotha-
lamic) could exert selective effects on feeding, but in other (ex-
trahypothalamic) regions such as the LS, activation of these ano-
rectic effects cannot be separated from the induction of stress-
related behaviors. Given the current epidemic of obesity in the
United States and the exigency to identify novel anorectic agents,
one must be mindful of the possibility that stimulation of certain
populations of CRF2 receptors might promote anorexia via the
induction of stress-like states when considering the potential util-
ity of CRF2 receptor agonists in this capacity.
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